eclipsebio.com

What It Is

Eclipsebio was founded in 2017 and is based in San Diego. It positions itself as a platform-style service provider for RNA drug development and RNA biology research. Rather than being general-purpose enterprise software in the traditional sense, it combines AI sequence design, rapid RNA prototyping, next-generation sequencing analysis, and bioinformatics reporting to provide R&D decision-making data for pharmaceutical companies, biotech firms, and academic institutions. The site states that it has served 300+ partners, including some leading biopharma companies.

Core Capabilities

Its core offering is eCOMPASS: an iterative closed loop that brings together design, make, and characterize, starting from an amino acid sequence and producing characterized RNA candidates. Individual capabilities include eNAVIGATE for predicting RNA-binding protein regulatory sites during the design stage, eMERGE for nucleotide-level analysis, and eVERSE for AI training data. Its experimental and analytics modules are fairly broad, including eSHAPE for structure probing, miR-eCLIP+ for detecting miRNA/siRNA binding and off-target effects, eRibo Pro for transcription and translation analysis, RBP-eCLIP, m6A-eCLIP, End-Seq, and Nanopore long-read sequencing.

Pricing and Delivery

The website does not disclose packages, pricing, a free plan, or a trial. Its pages repeatedly direct users to “Contact us” or “Talk to an RNA expert,” suggesting that it is closer to project-based scientific research services: scope is customized around goals such as RNA therapeutics, small oligonucleotides, small molecules, basic research, or AI data training. Teams that already have internal R&D capabilities may also purchase individual capabilities such as design optimization, nucleotide-level characterization, or coordination with manufacturing partners.

Pros and Cons

Its strengths lie in deep vertical specialization. It can address key questions in RNA drug development, such as structure, translation efficiency, sources of dsRNA contamination, off-target binding, m6A modifications, and protein-binding sites. Its experimental data can also support AI model training. The main limitation is the lack of standardized SaaS information: there is no visible self-service online workspace, permissions system, API documentation, compliance certifications, data security explanation, or payment method. Before procurement, buyers should focus on confirming sample handling, data ownership, delivery timelines, compliance requirements, and pricing.

Best Fit and Access from China

Eclipsebio is better suited to RNA drug companies, siRNA/ASO teams, AI drug discovery teams, CRO/R&D departments, and RNA biology labs. It is not a good fit for companies looking for general project management software or standard bioinformatics SaaS. Its accessibility from China cannot be determined from the available text alone, and payment methods are not disclosed. Domestic Chinese teams can compare it with Benchling, DNAnexus, Form Bio, and local sequencing/multi-omics service providers, but Eclipsebio’s main differentiation lies in its RNA-specific experiments and drug development interpretation capabilities.